Deals In Depth: July 2019
Executive Summary
Gilead continued its R&D relationship with Galapagos in a new, nearly $10bn alliance. Exact Sciences and Genomic Health merged in a $2.8bn agreement creating a leading global molecular diagnostics company. Pharma financing was down while device funding increased thanks to a strong showing in the debt category, including ResMed's $498m offering.